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Abstract: The low-density lipoprotein receptor-related protein 1 (LRP1) is a transmembrane
receptor, mediating endocytosis and activating intracellular signaling cascades. LRP1 is highly
expressed in the central nervous system (CNS), especially in oligodendrocyte precursor cells
(OPCs). Previous studies have suggested LRP1 as a regulator in early oligodendrocyte development,
repair of chemically induced white matter lesions, and cholesterol homeostasis. To circumvent
embryonic lethality observed in the case of global LRP1 deletion, we generated a new inducible
conditional knockout (KO) mouse model, which enabled an NG2-restricted LRP1 deficiency
(NG2-CreERT2ct2/wtxR26eGFPflox/floxxLRP1flox/flox). When characterizing our triple transgenic mouse
model, we noticed a substantial and progressive loss of recombined LRP1-deficient cells in the
oligodendrocyte lineage. On the other hand, we found comparable distributions and fractions of
oligodendroglia within the Corpus callosum of the KO and control animals, indicating a compensation
of these deficits. An initial study on experimental autoimmune encephalomyelitis (EAE) was
performed in triple transgenic and control mice and the cell biology of oligodendrocytes obtained
from the animals was studied in an in vitro myelination assay. Differences could be observed in these
assays, which, however, did not achieve statistical significance, presumably because the majority
of recombined LRP1-deficient cells has been replaced by non-recombined cells. Thus, the analysis
of the role of LRP1 in EAE will require the induction of acute recombination in the context of the
disease process. As LRP1 is necessary for the survival of OPCs in vivo, we assume that it will play an
important role in myelin repair.
Keywords: cre-recombinase; demyelination; experimental autoimmune encephalomyelitis (EAE);
glial progenitor cells; myelin; tamoxifen
1. Introduction
The low-density lipoprotein receptor-related protein 1 (LRP1) is a type-I transmembrane receptor.
It consists of two covalently bound subunits, an 85 kDa intracellular α-chain and 515 kDa extracellular
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β-chain [1]. As a multifunctional receptor, LRP1 can bind a variety of up to 40 different ligands such
as apolipoproteins (Apo), extracellular matrix molecules, and growth factors and is involved in their
endocytosis [1,2]. Apolipoproteins, especially ApoE, mediate cholesterol transport in various cell
types [3]. Beyond its endocytotic function, LRP1 is involved in intracellular signaling and can activate,
for example, the ERK and AKT pathways [4–6].
The LRP1 receptor is widely expressed in the body (liver, lung, blood vessels) and particularly in
the CNS [1,7,8]. Radial glia, neuroblasts, astrocytes, neurons, and especially oligodendrocyte precursor
cells (OPCs) serve as main sources for LRP1 [9–12]. In the past, many studies have focused on LRP1
and demonstrated that a global deletion of the receptor leads to embryonic lethality [13]. Therefore,
conditional Lrp1-knockout (KO) models have been developed. Previous studies have concentrated on
LRP1 function in oligodendrocytes, the myelinating macroglia in the CNS. Originating from highly
migratory and proliferative OPCs, which populate the forebrain, oligodendrocytes differentiate into
mature cells in their target compartment. Due to cytoskeletal rearrangements, myelin membrane
expansion of mature oligodendrocytes enables myelination, and thereby the electrical isolation of
nerve fibers [14–16].
It has been shown that neural stem cells, which lack LRP1, have a significantly reduced potential
to differentiate into OPCs, immature or mature oligodendrocytes, indicating a crucial role of LRP1 in
oligodendrogenesis [10,11]. Accordingly, LRP1 has been found highly expressed in OPCs, whereas it is
downregulated in mature, myelinating oligodendrocytes on both the mRNA and protein level [9,12,17].
This suggests a link between LRP1 and early oligodendrocyte development. Moreover, oligodendrocyte
functions are affected by LRP1. Thus, LRP1 deletion in chemically induced white matter lesions
revealed attenuated remyelination and compromised repair of white matter. Furthermore, cholesterol
homeostasis is regulated by LRP1, which plays a key role in oligodendrocyte differentiation [16].
According to the preliminary data, we generated a new inducible, conditional KO mouse
model with OPC-restricted LRP1-deficiency: NG2-CreERT2ct2/wtxR26eGFPflox/floxxLRP1flox/flox. NG2,
together with PDGFRα, serves as a marker for OPCs [18,19], which enabled us to delete LRP1 in
early oligodendrocyte development and analyze the ensuing effects of LRP1-deficiency on the whole
oligodendrocyte lineage. The characterization of our novel model revealed similar distributions and
fractions of oligodendroglia in the Corpus callosum. However, substantial and progressive loss of
recombined LRP1-deficient oligodendrocytes was observed over time. Moreover, when experimental
autoimmune encephalomyelitis (EAE) was elicited by immunization with a MOG peptide, the LRP1
KO animals were more strongly affected, with greater functional deficits in comparison to the control.
On the cellular level, the in vitro myelination assay revealed elongated internodes in the LRP1 KO
condition. Considering our findings, we propose that LRP1 is a critical long-term regulator of
oligodendrocyte survival in vivo and suggest a crucial role of LRP1 for myelin quality.
2. Materials and Methods
2.1. Ethics Statement
This study was carried out at the Ruhr-University Bochum with conformity to the recommendations
of local guidelines in experimental animal handling. The animal experiments were approved
by the “Landesamt für Natur, Umwelt, und Verbraucherschutz” (LANUV) in Recklinghausen,
North Rhine-Westphalia with the reference number 84-02.04.2015.A149. The study referred to
the 3Rs (Replacement, Reduction, Refinement) and tried to reduce animal numbers and refine
experimental conditions.
2.2. Generation of the New Mouse Model and Housing
The new mouse model was generated by cross-breeding previously described mouse lines.
LRP1flox/flox mice (B6;129S7-Lrp1tm2Her/J), which were obtained from the Jackson Laboratory, and the
transgenic constructs have been previously published by Rohlmann et al. [20]. In NG2-CreERT2NGCE
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mice, the inducible Cre DNA recombinase CreERT2 was knocked into the NG2 locus. Only
heterozygous mice were used [21]. By crossbreeding the mice to homozygous floxed reporter
mice [22], recombined cells could be identified by the genetically encoded GCaMP3 reporter
expression that can be detected by anti-GFP antibodies. Since we did not take advantage of
the Ca2+ indicating property of GCaMP3, we termed this reporter mouse line R26eGFPflox/flox.
By crossbreeding the two different mouse lines, NG2-CreERT2ct2/wtxR26eGFPflox/floxxLRP1flox/flox (KO)
and NG2-CreERT2wt/wtxR26eGFPflox/floxxLRP1flox/flox (control) animals were generated in one litter.
Both received tamoxifen via the lactating mother.
For in vivo analysis, postnatal day (P)7, P14, P21, P28, P42, P56, and P56–70 littermates were
analyzed. An in vitro myelination assay (Figure S1) required P6 to P9 animals.
Animals were housed in an open cage system with 12 h-day/night-cycles and 25 ◦C room
temperature. Water and diet were accessible ad libitum.
2.3. Genotyping
To genotype the littermates, genomic DNA from tail biopsies was used. All primers (Sigma,
St. Louis, MO, USA), amplified product sizes, and sources are listed in Table 1 (base pairs: bp, for:
forward, rev: reverse, WT: wildtype).
Table 1. Genotyping primers and amplified product sizes.





















KO: 245 bp [22]
2.4. Injection of Tamoxifen to Animals
The KO was induced via administration of tamoxifen. Therefore, feeding mothers were
intraperitoneally injected with 100 mg/kg tamoxifen (Sigma) dissolved in corn oil (Sigma), on two
consecutive days (Figure 1A). Maternal tamoxifen metabolites reached the pups via milk at postnatal
days (p)3 and 4 (referring to [21]). Animals were monitored and weighed every 2–3 days and evaluated
with a clinical score.
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Figure  1.  Recombination  efficiency  and  portion  of  recombined  cells  over  time.  (A)  Scheme  of 
tamoxifen  administration  and  analyzed  ages  of  experimental  animals.  (B)  Immunohistochemical 
stains against green fluorescent protein (GFP) indicating recombined cells within postnatal day (P) 
P7‐P42  KO  tissue  (scale  bars:  100  μm).  (C)  Quantification  of  GFP‐expressing  recombined  cell 
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To  further  assess  the  number  of  recombined  cells  that  could  be  attributed  to  the 
oligodendrocyte lineage, we employed the lineage‐specific marker Olig2 and analyzed the number 
of cells double‐positive  for GFP and Olig2. At P7, half of all oligodendrocytic Olig2‐positive cells 
expressed  GFP  and  revealed  a  recombination  efficiency  of  50%  recombined  LRP1‐deficient 
oligodendrocytes.  Surprisingly,  we  saw  a  significant  reduction  in  the  number  of  recombined 
i 1. Recombination efficiency and portion of recombined cells over time. (A) Scheme of tamoxifen
administration a d analyzed ages of experimental animals. (B) Immunohistoche ical stains against
green fluore cent protein (GFP) indicati g recombined cells within postnatal day (P) P7-P42 KO tissue
(scale bars: 100 µm). (C) Quantification of GFP-expressing rec mbined cell fractions in the Corpus
callosum of various analyzed stages. (D) Representative immunohistochemical staining agains GFP
and Olig2 (scale bars: 100 µm, 20 µm). (E) Quantification of double-positive cells for GFP and Ol g2,
defined as recombination efficiency, indicated an initial effi iency of mor than 50%, before a significant
and progressive loss of double-positive recombi ed LRP1 KO ol godendrocytes was bserved over time.
At 56, the loss of double-positive cell compared to earlier time points reached statistical significance,
whereas this effect was not that promin nt at P42 (p ≤ 0.05 for *, p ≤ 0.01 for **, and p < 0.001 for ***).
Data ar expressed as the mean ± SEM. N = 3–4, = 9–12 per rostral and caudal art. At least 200–1200
cells per section were counted. Depe ing on normally or not normally di tribut d data, the Student’s
t-test or Man –Whitney U test was used for eval ation within the individual ages.
2.5. Decapitation, Perfusion, and Dissection
F r the experim nts, P7 animals were decapitated, wh reas P14, P21, P28, P42, P56, and P56–70
animals were anesthetized (100 mg/kg ketami (CP-Pharma, Burgdorf, Germany), 10 mg/kg Xylazin
(CP-Pharma)), and perfused with PBS/heparin (Ratiopharm, Ulm, G rmany). Therefore, a constant
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pressure of 0.7 mL/min was generated with a peristaltic pump. After perfusion for 10–15 min, the
animals were dissected. For all ages, the brains were removed from the skull and separated into
hemispheres for cryosections, PCR, and western blot analysis.
2.6. Cryosections
For cryosections, the dissected tissue was postfixed in 4% paraformaldehyde (PFA; Carl Roth
GmbH and Co. KG, Karlsruhe, Germany) overnight and afterward drained with 20% sucrose (Fisher
Chemical by Thermo Fisher Scientific, Bedford, MA, USA), again overnight. The tissue was embedded
in tissue freezing medium (Leica Biosystems, Mount Waverly, Australia) to prepare sagittal cryosections
(14 µm). Cryosections were stored at −20 ◦C until further use.
2.7. Immunohistochemistry (IHC)
Intranuclear immunohistochemical staining started with incubation for 1 h in citrate buffer
(solution A: 0.1 M citric acid-1-hydrate, solution B: 0.1 M Na-citrate-dihydrate; 1 mM of solution A and
4 mM of solution B in Aqua dest) at 70 ◦C. After three washes with PBS (10 × PBS: 137 mM NaCl, 3 mM
KCl, 6.5 mM Na2HPO4•2H2O, 1.5 mM KH2PO4 in Aqua dest; 1 × PBS: 10 × PBS in Aqua dest, pH 7.4),
blocking buffer (PBS, 0.1% Triton X-100, 1% bovine serum albumin (BSA, Sigma), 3% serum (Dianova
GmbH, Hamburg, Germany)) was added to the slices for 1 h. The primary antibody was dissolved in
blocking buffer and incubated on the sections overnight at 4 ◦C. Next, three washing steps with PBS
followed and secondary antibody, dissolved in blocking buffer, was added for 2 h at room temperature.
Finally, three washing steps in PBS and mounting with ImmuMount (Thermo Fisher Scientific) and
coverslips were performed. Extranuclear immunohistochemical staining started with three PBS washes
and followed the same protocol as described above. Antibodies: APC (clone CC1, 1:100, ab16794,
Lot: GR322482-3, Abcam; Cambridge, UK), GFP (1:200, AB3080; Lot 2929345, Millipore by Merck,
Darmstadt, Germany; 1:500, 600-101-215, Lot: 33301, Rockland Immunochemicals Inc., Limerick, PA,
USA), LRP1 (1:500, ab92544, Lot: 6R259330-27, Abcam), Olig2 (1:400, AB9610, Lot: 3071572, Millipore),
PDGFRα (1:300, sc-338, Lot: E2015, Santa Cruz Biotechnologies Inc., Dallas, TX, USA), Donkey α rabbit
AF488 (1:250, 711-545-152, Lot: 127498, Jackson ImmunoResearch Laboratories Inc., West Grove, PA,
USA), Donkey α rabbit Cy3 (1:500, 711-165-152, Lot: 130990, Jackson ImmunoResearch Laboratories
Inc.), Donkey α mouse Cy5 (1:150, 715-175-150, Lot: 129945, Jackson ImmunoResearch Laboratories
Inc.), rabbit α mouse Cy3 (1:500, 315-165-044, Lot: 131676, Jackson ImmunoResearch Laboratories Inc.),
Donkey α goat AF488 (1:250, 705-545-147, Lot: 136089, Jackson ImmunoResearch Laboratories Inc.),
and Donkey α goat Cy3 (1:500, 705-165-147, Lot: 139052, Jackson ImmunoResearch Laboratories Inc.).
2.8. Preparation of Tissue for Reverse Transcriptase-Polymerase Chain Reaction(RT-PCR) and Western
Blot Analysis
For the PCR and western blot analysis, brain hemispheres were shortly thawed and Corpora
callosa were dissected from the tissue with disposable scalpels (B. Braun, Melsungen, Germany).
Afterward, the tissue was lysed with mRNA lysis buffer (Sigma: GenElute Mammalian Total RNA
Miniprep Kit) or protein lysis buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% Triton
X-100, 0.1% SDS, 0.1% Na-deoxycholate).
2.9. RT-PCR Analysis
To investigate mRNA expression in the tissue samples, mRNA was isolated from lysates and
cDNA was synthesized following the manufacturer’s instructions (Sigma: GenElute Mammalian Total
RNA Miniprep Kit, Thermo Fisher Scientific: First Strand cDNA Synthesis Kit). Via RT-PCR β-actin
(for: TAT GCC AAC ACA GTG CTG TCT GGT GG, rev: TAG AAG CAT TTG CGG TGG ACA ATG G),
Mbp (for: TCT CAG CCC TGA CTT GTT CC, rev: ATC AAC CAT CAC CTG CCT TC) and Pdgfrα
(for: GCA CCA AGT CAG GTC CCA TT, rev: CTT CAC TGG TGG CAT GGT CA) were amplified.
All primers were from Sigma.
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2.10. Western Blot Analysis
Proteins were separated by weight in 12% polyacrylamide-SDS-gels and transferred after to
PVDF-membranes (Carl Roth) using a semi-dry transblot system (Carl Roth). Membranes were blocked
with 5% skimmed milk powder (Heirler, Radolfzell, Germany) in tris-buffered saline with Tween TBST
(0.05% Tween-20, 1 × TBS; 10 × TBS: 250 mM Tris/HCl pH 7.4, 1.5 M NaCl) (blocking solution) for 1 h.
Membranes were incubated in primary antibody, dissolved in blocking solution at 4 ◦C overnight,
followed by three washing steps in TBST. Next, a one-hour incubation with the secondary antibody,
which was dissolved in blocking solution, and finally, three washing steps with TBST and one wash
with 1 × TBS were carried out. Western blots were developed after incubation with the substrate
solution (ECL Substrate, BioRad Lab. Inc., Hercules, CA, USA) for 5 min. Antibodies: LRP1 (1:10,000,
ab92544, Lot: 6R259330-27, Abcam), MBP (1:1000, MCA409S, Lot: 161031A, BioRad), PDGFRα (1:10,000,
sc-338, Lot: E2015, Santa Cruz), α-tubulin (1:10,000, T9026, Lot: 078M4796 V, Sigma), Goat α rabbit
HRP (1:5000, 111-035-144, Lot: 132409, Jackson ImmunoResearch Laboratories Inc.), Goat α mouse
HRP (1:10,000, 115-035-068, Lot: 132223, Jackson ImmunoResearch Laboratories Inc.), and Goat α rat
(1:5000, 112-035-062, Lot: 90553, Jackson ImmunoResearch Laboratories Inc.).
2.11. Experimental Autoimmune Encephalomyelitis (EAE)
For the analysis of the functional effects of LRP1 on oligodendrocytes, experimental allergic
encephalomyelitis (EAE) was induced. Tamoxifen-treated animals were generated and immunized
with MOG35–55 peptide (synthesized at Charité Berlin, Germany) in complete Freund’s adjuvant
(incomplete Freund-adjuvant, M. tuberculosis H37 Ra, Difco Laboratories, Detroit, MI, USA) at the
age of 8–10 weeks (P56–P70). Additionally, the animals received 250 ng/100 µL pertussis toxin (EMD
Millipore Corporation by Merck) on the day of and two days after immunization. Clinical symptoms
were evaluated using a 10-point-score scale (0 = normal, 1 = reduced tail tonus, 2 = complete tail
palsy, 3 = lack of reflexive compensatory movements while walking, 4 = ataxia, 5 = slight paralysis of
the hind legs, 6 = plegia of one leg or moderate paralysis of both legs, 7 = paraplegia with complete
paralysis of both hind legs, 8 = tetraparesis with (slight) paralysis of front extremities, 9 = moribund,
and 10 = death) and score and weight were documented on a daily basis. After 28 days of monitoring
the course of disease, the experiment was stopped and the animals were sacrificed.
2.12. Imaging
Immunohistochemical stains were documented with AxioZoom V16, AxioCam 506mono, and Zen
2009 software by Zeiss (Oberkochen, Germany). Three caudal and three rostral images of each Corpus
callosum were taken. RT-PCR results were kept by a documentation system from LTF Labortechnik
(Wasserburg, Germany) with BioCaptw software. Protein gels and western blots were imaged with
the documentation system MicroChemi and Gel Capture 6.6 software by DNR bio imaging systems
(Jerusalem, Israel).
2.13. Quantification
Immunohistochemical stains were quantified by single cell counting in ImageJ/FIJI. Single cells
were defined by nuclear stain with Hoechst dye, binding to nucleic acids. Immuno-positive cells were
identified by expression of stage- or lineage-specific markers, depending on their expected localization
(intranuclear, intracellular, extracellular). Three caudal and rostral sections of the Corpus callosum in
the sagittal orientation were taken and at least 200–1200 cells per section were counted.
mRNA and protein expression were measured by intensity measurements in ImageJ/FIJI.
In some cases, significant reductions between two conditions were additionally calculated and
mentioned in the text. Therefore, the higher value served as 100%.
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2.14. Statistics
Statistics were depicted as mean ± SEM. Normal distribution of values was checked with the
Shapiro–Wilk test. Depending on normally or not normally distributed values, the Student’s t-test or
Mann–Whitney U test was performed. Biological replicates were stated as “N” and technical replicates
as “n”. Immunohistochemical stains: N = 3–4, n = 9–12; PCR analysis: N = 4, n = 4; western blot
analysis: N = 3, n = 3; EAE pilot study: N = 5, n = 5. Significant data were declared with a p-value (p)
of 0.05. p ≤ 0.05 for *, p ≤ 0.01 for ** and p < 0.001 for ***. All statistical tests were performed with
Microsoft Excel (Redmond, WA, USA).
3. Results
3.1. Induction of the NG2-Restricted LRP1-Deficient KO in the New Mouse Model
In order to investigate the role of LRP1 in the NG2-cell lineage, we generated the novel
conditional knockout mouse model: NG2-CreERT2ct2/wtxR26eGFPflox/floxxLRP1flox/flox (KO) and
NG2-CreERT2wt/wtxR26eGFPflox/floxxLRP1flox/flox (control). To induce the deletion, tamoxifen was
applied to lactating mothers three and four days after the birth of the litters. For the analysis, we
focused on six different age stages to evaluate different experimental aspects (Figure 1A).
First, we focused on the number of cells that recombined upon tamoxifen treatment by monitoring
the expression of the reporter GCaMP3 detectable by anti-GFP antibodies. For the sake of simplicity,
we refer to GCamP3-expressing cells as GFP- or reporter-expressing cells. Cells were counted in the
Corpus callosum because this brain region represents a strongly myelinated fiber tract. Overall cell
numbers were visualized using a nuclear marker (Hoechst dye) and the proportion of immunostained
cells was recorded. Postnatally from P7 to P42, an increase in the number of GFP-expressing cells
could be observed, before the fraction of immunopositive cells dropped rapidly at P56 (Figure 1B,C).
For the rostral Corpus callosum, a range of maximally 31% ± 4.9% standard error of the mean (SEM)
and minimally 7% ± 1.6% SEM was found over time. Similar to this finding, a maximum of 27%
± 9% SEM and a minimum of 4.7% ± 1.4% GFP-positive cells was present in the caudal region
of the Corpus callosum (Figure 1C). These results suggest that initially from P7 to P42, about one
third of the cells in the Corpus callosum showed Cre-mediated recombination, which represents the
percentage of oligodendrocyte lineage cells generated by NG2 cells present at P3 to P5 at the time of
tamoxifen injection.
To further assess the number of recombined cells that could be attributed to the oligodendrocyte
lineage, we employed the lineage-specific marker Olig2 and analyzed the number of cells
double-positive for GFP and Olig2. At P7, half of all oligodendrocytic Olig2-positive cells expressed
GFP and revealed a recombination efficiency of 50% recombined LRP1-deficient oligodendrocytes.
Surprisingly, we saw a significant reduction in the number of recombined oligodendrocytes over time
(Figure 1D,E). Focusing at the maximum at P7, fractions of 53% ± 9.9% SEM rostrally and 59% ±
6.7% SEM caudally of GFP-expressing Olig2-positive cells were identified for the Corpus callosum.
Reflecting a loss of recombined oligodendrocytes, a minimum of only 15% ± 6.6% SEM (rostral) and
13% ± 2.8% SEM (caudal) of GFP-expressing Olig2-positive cells was left at P56. Setting these fractions
in relation to the starting point at P7, this signifies a rostral and caudal reduction of recombined
oligodendrocyte lineage cells by 71.1% (53% ± 9.9% SEM reduced to 15% ± 6.6% SEM) and 77.3%
(59% ± 6.7% SEM reduced to 13% ± 2.8% SEM), respectively. This strong effect illustrated a clear
linkage between LRP1 expression and oligodendrocyte lineage cell survival. The most straightforward
explanation for the progressive loss of recombined cells in the Olig2-lineage is presumably cell death
as a consequence of LRP1 elimination.
3.2. LRP1 Expression in Oligodendrocyte Development
The new mouse model aims at LRP1-deficiency in OPCs and differentiating oligodendrocytes.
Therefore, the analysis of LRP1-expressing cells was vitally important for the characterization of
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the model and the impact of LRP1 on oligodendrocytes. So, we performed immunohistochemical
staining against LRP1 in relation to all cells assessed by nuclear stain (Figure 2 and Figure S2).
Previous studies have demonstrated a decrease in LRP1-expression on the mRNA and protein level
in the oligodendrocyte lineage during development [9,12], which was verified in our model during
development with LRP1-expressing cells. LRP1-positive cells declined from P7 (Con maximum:
9.0% ± 1.9% SEM) to P56 (Con maximum: 0.2% ± 0.3% SEM) (Figure 2A,B). To assess the success
of LRP1 deletion on protein level immunohistochemical staining against LRP1 were performed.
Here, comparable fractions of LRP1-positive cells were observed in the KO when compared to
the control at P7 (Con maximum: 9.0% ± 1.9%; KO maximum: 7.6 ± 2.0%). This indicates an
incomplete recombination, or rather incomplete degradation of LRP1, at this time point shortly after
tamoxifen-mediated induction. Notable differences were observed at P14 and P21, with significantly
reduced fractions of LRP1-expressing cells in the KO when compared to the control. This demonstrated
a successful recombination in terms of LRP1 deletion and the degradation of LRP1. In detail, we found
a significant reduction by 72% (2.8% ± 1.4% SEM reduced to 0.8% ± 0.5% SEM) of LRP1-expressing cells
from the control to KO condition at P14 in the caudal Corpus callosum (p ≤ 0.05, *). One week later,
highly significant reductions by 85% (2.1% ± 0.2% SEM reduced to 0.3% ± 0.3% SEM) rostrally and 73%
(1.9% ± 0.5% SEM reduced to 0.5% ± 0.4% SEM) caudally in comparison with the control were shown
for the KO at P21 (p ≤ 0.01 **; p ≤ 0.001 ***). Thus, a KO-dependent decrease in the LRP1-expressing
cells was observed that confirmed the success of the inducible KO strategy. Accordingly, the loss of
LRP1 in these cells might account for the previously detected reduced proportion of recombined cells
(see above).
Strikingly, a significant difference between the control and KO was observed at P56. Whereas no
LRP1-positive cells were found in the caudal Corpus callosum of the control, 0.5% of the cells expressed
LRP1 in the KO (* p ≤ 0.05).
In a complementary approach, we analyzed the time-dependent change of the cell fraction still
double-positive for GFP and LRP1. This fraction represents the surviving cells of the oligodendrocyte
lineage due to still incomplete protein degradation [23]. Immunohistochemical staining against LRP1
and GFP revealed a maximum at P7 with 2.4% ± 0.5% SEM (rostral) and 3.5% ± 0.7% SEM (caudal) of
LRP1- and GFP-double-expressing cells. Within the next seven days, the fraction of double-positive
cells dropped rapidly to 0.5% and less, and at P56, a minimum of 0.02% ± 0.03% SEM (rostral) and 0%
(caudal) remained (Figure 2A,C). In conclusion, more than 95% of cells with recombined, and therefore
activated reporter were devoid of LRP1 protein.
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reporter‐positive  cells  that  still  expressed  non‐degraded  LRP1  (scale  bars:  100  μm,  20  μm).  (B) 
Quantification of LRP1+‐cells  indicated a  time‐dependent reduction and proved  the success of  the 
inducible KO strategy with significantly reduced numbers of LRP1‐expressing cells in the KO at P14 
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Fig re 2. LRP1-expressing cells decreased over time. (A) Immunohistochemical staining against LRP1
and GFP to identify LRP1-expressing cells and double-positive cells, indicating reporter-positive cells
that still expressed non-degraded LRP1 (scale bars: 100 µm, 20 µm). (B) Quantification of LRP1+-cells
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3.3. Proportion and Distribution of Control and KO Cells
In order to investigate the LRP1 KO-dependent effects specifically in the oligodendrocyte lineage,
we analyzed the proportion and distribution of immature and mature oligodendrocytes in vivo. To this
end, we prepared triple immunostainings to define different subpopulations of oligodendrocytes
(Figure 3).




oligodendrocyte  lineage  in  the Corpus  callosum  by Olig2, CC1,  and GFP.  Immunohistochemical 
stainings of P7–P56 control and KO tissue against Olig2, GFP, and CC1 (mature con cells defined as: 
Olig2+/CC1+/GFP−;  mature  KO  cells:  Olig2+/CC1+/GFP+;  immature  con  cells  defined  as: 
Olig2+/CC1−/GFP−; immature KO cells: Olig2+/CC1−/GFP+) (scale bars: 100 μm, 20 μm). 






Overall,  the  distribution  of mature  and  immature  oligodendrocytes  in  both  genotypes was 
comparable at the individual postnatal age stages. However, the proportion of immature KO cells 
increased  after  P21, whereas  the  relating  ratio  of mature  cells  decreased  in  this  LRP1‐deficient 
fraction.  In  fact,  our  data  suggest  that  although  progressive  elimination  of Olig2‐positive  cells 
without LRP1 expression was observed via  the  loss of Olig2/GFP‐double positive cells  (Figures 1 
and 4), the remaining fractions of oligodendrocyte lineage cells within the Corpus callosum revealed 
comparable  characteristics. We  assumed  a  compensatory  effect  by  regenerative  healthy  cells  at 
regions of progressive cell loss. The smaller proportion of remaining, recombined KO cells behaved 
similarly with  regard  to distribution and differentiation  in  the Corpus callosum compared  to  the 
control cells.   
Figure 3. Triple immunohistochemical stainings showing mature and immature proportions within
oligodendrocyte lineage in the Corpus callosum by Olig2, CC1, and GFP. Immunohistochemical
stainings of P7–P56 control and KO tissue against Olig2, GFP, and CC1 (mature con cells defined
as: Olig2+/CC1+/GFP−; mature KO cells: Olig2+/CC1+/GFP+; immature con cells defined as:
Olig2+/CC1−/GFP−; immature KO cells: Olig2+/CC1−/GFP+) (scale bars: 100 µm, 20 µm).
Olig2 was used to label all oligodendrocytic cells. CC1-expressing cells were defined as
mature oligodendrocytes, whereas CC1-negative cells were considered as immature cells. Based
on the expression of GFP, KO cells (recombined) could be discriminated from non-recombined cells
within the KO tissue. In this approach, mature oligodendrocytes were visualized by the marker
combinations Olig2+/CC1+/GFP− (control; non-recombined in control tissue) and Olig2+/CC1+/GFP+
(KO; recombined in KO tissue). Immature oligodendrocytes were identified as Olig2+/CC1−/GFP−
(control; non-recombined in control tissue) and Olig2+/CC1−/GFP+ (KO; recombined in KO tissue)
(Figures 3–5).
First, the total numbers of Olig2-expressing cells served as references (100% value for the control
and KO) for the analysis of mature and immature oligodendrocyte proportions in the control and
KO tissue (Figures 4 and 5). For mature oligodendrocytes, an increase from P7 to P56 was observed
in the control animals (rostral: 23.0% ± 3.9% to 67.8% ± 6.4%; caudal: 25.4% ± 1.7% to 66.6% ±
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12.0%). However, the KO fraction supported our previously found progressive loss of LRP1-deficient
oligodendrocytes with decreasing proportions in mature cells during development (rostral: 15.5% ±
3.2% to 5.7 ± 1.9%; caudal: 14.6% ± 3.3% to 8.6% ± 3.2%). For this comparison a highly significant
impairment of the KO condition was observed when compared to the control (* p ≤ 0.05; ** p ≤ 0.01; ***
p ≤ 0.001).




fractions  in  the  KO  when  compared  to  the  control,  indicating  a  progressive  cell  loss.  (A) 
Quantification  of  mature  proportions  of  recombined  (Olig2+/CC1+/GFP+)  and  non‐recombined 
oligodendrocytes  (Olig2+/CC1+/GFP−), normalized  to Olig2‐positive  cells  indicated a  significantly 
impaired KO fraction compared to the control (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). This observation 
demonstrated  a  progressive  loss  of  LRP1‐deficient  oligodendrocytes  during  development.  (B) 
Quantification of  immature proportions of  recombined  (Olig2+/CC1−/GFP+)  and non‐recombined 
oligodendrocytes  (Olig2+/CC1−/GFP−),  normalized  to  Olig2‐positive  cells  showed  comparable 
results  to  the  mature  proportions.  A  significantly  reduced  fraction  of  LRP1‐deficient 
oligodendrocytes developed over time (*** p ≤ 0.001). Data are expressed as mean ± SEM. N = 3–4, n = 
9–12 per  rostral and caudal part. At  least 200–1200 cells per  section were counted. Depending on 
normally or not normally distributed data, the Student’s t‐test or Mann–Whitney U test was used for 
evaluation within the individual ages. 
Figure 4. Comparison of mature and immature oligodendrocytes revealed significantly decreased
fractions in the KO when compared to the control, indicating a progressive cell loss. (A) Quantification
of mature proportions of recombined (Olig2+/CC1+/GFP+) and non-recombined oligodendrocytes
(Olig2+/CC1+/GFP−), normalized to Olig2-positive cells indicated a significantly impaired KO fraction
compared to the control (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). This observation demonstrated
a progressive loss of LRP1-deficient oligodendrocytes during development. (B) Quantification of
immature proportions of recombined (Olig2+/CC1−/GFP+) and non-recombined oligodendrocytes
(Olig2+/CC1−/GFP−), normalized to Olig2-positive cells showed comparable results to the mature
proportions. A significantly reduced fraction of LRP1-deficient oligodendrocytes developed over time
(*** p ≤ 0.001). Data are expressed as mean ± SEM. N = 3–4, n = 9–12 per rostral and caudal part.
At least 200–1200 cells per section were counted. Depending on normally or not normally distributed
data, the Student’s t-test or Mann–Whitney U test was used for evaluation within the individual ages.
Furthermore, immature oligodendrocytes were investigated from P7 to P56 and revealed
decreasing cell proportions for the control condition (rostral: 77.0% ± 8.0% to 32.2% ± 4.9%; caudal:
74.6% ± 10.5% to 33.4% ± 7.4%). Similar to mature LRP1-deficient KO oligodendrocytes, the proportion
of immature KO cells also decreased over time (rostral: 37.2% ± 6.1% to 6.0% ± 3.7%; caudal: 42.8% ±
6.5% to 6.9% ± 3.9%). Again, a highly significant difference was seen between the control and the KO
condition (*** p ≤ 0.001). In summary, these findings support our previously shown data (Figure 1)
Cells 2019, 8, 1550 12 of 23
regarding the progressive loss of LRP1-deficient oligodendrocytes compared to the control condition
and the LRP1-dependent survival of oligodendrocytes.
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Figure  5.  Proportions  of  persisting mature  and  immature  oligodendrocyte  lineage  cells  revealed 
similar  differentiation  and  distribution  in  the KO  condition when  compared  to  the  control.  (A) 
Quantification of mature control oligodendrocyte proportions (Olig2+/CC1+/GFP− cells) normalized 
to Olig2+‐cells revealed an  increase  from 20%  to 65% over  time.  (A’) Quantification of mature KO 
oligodendrocyte proportions (Olig2+/CC1+/GFP+‐cells) normalized to recombined Olig2+/GFP+‐cells 
demonstrated  an  increase  from  P7  to  P21  and  comparable  cell  proportions  afterwards.  (B) 
Quantification  of  immature  control  oligodendrocyte  proportions  (Olig2+/CC1−/GFP‐cells) 
normalized to Olig2+‐cells exhibited decreasing proportions from 80% to 30% during development. 
(B’)  Quantification  of  immature  KO  oligodendrocyte  proportions  (Olig2+/CC1−/GFP+‐cells) 
normalized to Olig2+/GFP+‐cells indicated a slight decrease over time. Please note that the presented 
proportions of mature and immature KO cells refer to the progressively decreasing recombined KO 
fraction  (see  Figure  1E).  The  minority  of  surviving  LRP1‐negative  oligodendrocytes  behaved 
similarly to the control. No statistically significant differences were observed between the KO and 
control conditions. Data are expressed as the mean ± SEM. N = 3–4, n = 9–12 per rostral and caudal 









various  differentiation  stages  (e.g.,  precursors  and mature  cells) were  investigated.  To  this  end, 
immunohistochemical  stainings,  using  the  lineage  marker  Olig2  (including  OPCs  and  mature 
oligodendrocytes),  the OPC marker PDGFRα  (only OPCs),  and  the mature marker CC1  (mature 
oligodendrocytes only) were performed (Figure 6). Proportions of labeled cells were determined in 
Figure 5. Proportions of persisting mature and immature oligodendrocyte lineage cells revealed similar
differentiation and distribution in the KO condition when compared to the control. (A) Quantification
of mature control oligodendrocyte proportions (Olig2+/CC1+/GFP− cells) normalized to Olig2+-cells
revealed an increase from 20% to 65% over time. (A’) Quantification of mature KO oligodendrocyte
proportions (Olig2+/CC1+/GFP+-cells) normalized to recombined Olig2+/GFP+-cells demonstrated an
increase from P7 to P21 and comparable cell proportions afterwards. (B) Quantification of immature
control oligodendrocyte proportions (Olig2+/CC1−/GFP-cells) normalized to Olig2+-cells exhibited
decreasing proportions from 80% to 30% during development. (B’) Quantification of immature KO
oligodendrocyte proportions (Olig2+/CC1−/GFP+-cells) normalized to Olig2+/GFP+-cells indicated
a slight decrease over time. Please note that the presented proportions of mature and immature KO
cells refer to the progressively decreasing recombined KO fraction (see Figure 1E). The minority of
surviving LRP1-negative oligodendrocytes behaved similarly to the control. No statistically significant
differences were observed between the KO and control conditions. Data are expressed as the mean ±
SEM. N = 3–4, n = 9–12 per rostral and caudal part. At least 200–1200 cells per section were counted.
Depending on normally or not normally distributed data, the Student’s t-test or Mann–Whitney U test
were used for evaluation within the individual ages.
In a further step, Olig2- (in the control tissue) as well as Olig2- and GFP-double expression
(recombined cells in the KO tissue) were used to label the whole oligodendrocyte lineage fractions
(100% reference values for the control and KO, respectively) (Figures 3 and 5). For this aspect, it is
important to note that the following data showed relative proportions of mature/immature cells within
the recombined LRP1-free cell fraction compared to the control. As shown in Figures 1 and 4, this
recombined cell fraction was strongly reduced over time (compare Figure 1 reduction rostral: 71.1%,
value: 53% ± 9.9% SEM reduced to 15% ± 6.6% SEM; reduction caudal: 77.3%, value: 59% ± 6.7% SEM
reduced to 13% ± 2.8% SEM; see also Figure 4 and description above). This means that the absolute
numbers of such KO cells found in the Corpus callosum were much lower than the control.
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Focusing on the proportion of mature cells, a non-linear increase over time was observed
(minimum: 23.0% ± 3.9% SEM, maximum: 67.8% ± 6.4% SEM) (Figure 5A,A’). At P21, the first peak
was reached and the maximum of KO oligodendrocytes (67.8% ± 6.4% SEM) was detected, which
slightly decreased until P56 (minimum 48.5% ± 16.4% SEM) (Figure 5A’). In contrast, the control
condition revealed the opposite effect with a maximum at P56 (P21: 52.3% ± 10.6% SEM; P56: 67.8% ±
6.4% SEM) (Figure 5A).
The proportion of immature cells tended to decrease (Figure 5B,B’). From P7 to P21, a clear
reduction in the fraction of immature cells was observed (maximum: 77.0% ± 8.0% SEM, minimum:
38.3% ± 13.3% SEM), which was comparable in both genotypes. Thereafter, the control cell fraction
remained stable until P42 and finally decreased until P56 (minimum: 32.2% ± 4.9% SEM) (Figure 5B).
Focusing on the KO, an increase to P42 (maximum: 61.3% ± 19.7% SEM) was determined, followed by
a slight decrease until P56 (minimum: 44.7% ± 25.1% SEM) (Figure 5B’).
Overall, the distribution of mature and immature oligodendrocytes in both genotypes was
comparable at the individual postnatal age stages. However, the proportion of immature KO cells
increased after P21, whereas the relating ratio of mature cells decreased in this LRP1-deficient
fraction. In fact, our data suggest that although progressive elimination of Olig2-positive cells
without LRP1 expression was observed via the loss of Olig2/GFP-double positive cells (Figures 1
and 4), the remaining fractions of oligodendrocyte lineage cells within the Corpus callosum revealed
comparable characteristics. We assumed a compensatory effect by regenerative healthy cells at regions
of progressive cell loss. The smaller proportion of remaining, recombined KO cells behaved similarly
with regard to distribution and differentiation in the Corpus callosum compared to the control cells.
3.4. Cellular Characterization of Oligodendrocyte Lineage-Specific Cells
After the evaluation of the KO and successful recombination, we wanted to exclude side-effects
on the oligodendrocyte population due to the tamoxifen-induced recombination. We aimed to
compare oligodendrocyte lineage cell fractions in the Corpus callosum in a genotype-independent
manner (including GFP+ and GFP− cells in the tissue) to validate potential gross differences in tissue
composition between the control and KO animals. Therefore, subpopulations of oligodendrocytes of
various differentiation stages (e.g., precursors and mature cells) were investigated. To this end,
immunohistochemical stainings, using the lineage marker Olig2 (including OPCs and mature
oligodendrocytes), the OPC marker PDGFRα (only OPCs), and the mature marker CC1 (mature
oligodendrocytes only) were performed (Figure 6). Proportions of labeled cells were determined in
relation to the overall cell number as revealed by staining the cell nuclei (Figure 6; see alternative
analysis in Figure S3).
Focusing on the total number of Olig2-positive cells, we found slightly increasing numbers over
time in both genotypes, starting with a minimum of 28.6% ± 3.8% SEM in the rostral KO Corpus
callosum at P7, and reaching a maximum fraction of 65.9% ± 19.1% SEM in the rostral part at P56
(Figure 6A,B). Furthermore at P7 and P21, the KO conditions showed significantly different distributions
of Olig2-positive cells within the Corpus callosum (* p ≤ 0.05; ** p ≤ 0.01). These can be explained
with rostro-caudal differences due to differentiation, myelination, and development, which were
the reason for the region-specific analysis in the present study [24–28]. As expected, the number of
oligodendrocyte lineage cells in the Corpus callosum augmented with time.
Proceeding more specifically with progenitor and mature oligodendrocyte fractions, we noted
inverse effects (Figure 6C,D). PDGFRα-positive OPCs decreased over time in the control and KO,
starting with 17.8% ± 1.9% SEM (maximum, caudal, control) at P7, whereas only 0.9% ± 0.3% SEM
(minimum, caudal, control) immunopositive cells remained in the adult stage at P56 (Figure 6C).
In addition, a significantly increased OPC-fraction was observed at P56 for the KO in the rostral Corpus
callosum compared to the control (** p ≤ 0.01). In contrast, CC1-positive mature oligodendrocytes
tended to increase within the first four weeks (until P28) (increase: 15%; value: 23.1% ± 2.7% SEM up to
44.3% ± 10.4% SEM) and surprisingly decreased afterward (reduction: 28%; value: 44.3 % ± 10.4% SEM
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reduced to 15.9% ± 3.8% SEM) (Figure 6D). Thus, the OPC population progressively matured, losing
the PDGFRα marker, and expressing CC1. These data support the interpretation that the progressive
loss of recombined LRP1-deleted oligodendrocytes is compensated by non-affected cells.





Figure  6.  Analysis  of  stage‐specific  oligodendrocyte  markers.  (A)  Representative 
immunohistochemical stainings against Olig2 and GFP for the control and KO animals at P7 and P56 
(scale bars: 100 μm, 20 μm). (B) Quantification of Olig2+‐cells indicated a slight increase over time 
with similar results  for both genotypes. Significant caudo‐rostral differences were observed  in  the 








Figure 6. Analysis of stage-specific oligodendrocyte markers. (A) Representative immunohistochemical
stainings against Olig2 and GFP for the control and KO animals at P7 and P56 (scale bars: 100 µm,
20 µm). (B) Quantification of Olig2+-cells indicated a slight increase over time with similar results for
both genotypes. Significant caudo-rostral differences were observed in the KO at P7 and P21 (* p ≤ 0.05;
** p ≤ 0.01). (C) Quantification of PDGFRα+-OPCs from P7 to P56, demonstrating globally decreasing
cell numbers and a significantly igher proportion of precursors in the KO when com ared to the
control at P56 (** p ≤ 0.01). (D) Quantific t on of CC1-ex ressing mature oligodendrocytes revealed
increasing numb rs up to P28, follo d by a decrease afterw rd. No differ nce was detectable between
the control and KO. Data are expressed as mean ± SEM. N = 3–4, n = 9–12 per rostral and caudal part.
At least 200–1200 cells per section were counted. Depending on normally or not normally distributed
data, the Student’s t-test or Mann–Whitney U test were used for evaluation within the individual ages
(see supplementary analysis in Figure S3).
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3.5. Molecular Characterization of Oligodendrocyte Lineage-Specific Cells
The above-mentioned results of the cellular characterization of oligodendrocytic cells by
immunohistology were complemented by RT-PCR and western blot analysis referring to PDGFRα
and MBP (myelin basic protein, a mature myelin marker) expression on the mRNA and protein
level. Corpora callosa of the control and KO animals were prepared (Figure 7). In agreement with
the results of immunohistochemistry, the RT-PCR and western blot results demonstrated increasing
levels of the mature marker MBP and decreasing levels of the OPC marker PDGFRα over time
(Figure 7A–E). Overall PCR and western blot analysis generally confirmed the previous findings
obtained by immunohistochemistry, where a comparable outcome of oligodendrocyte maturation in
both genotypes was observed. However, as an exception, we saw a significantly upregulated relative
Mbp mRNA expression in the KO when compared to the control at P14 (** p ≤ 0.01).












or  not  normally  distributed  data,  the  Student’s  t‐test  or  Mann–Whitney  U  test  was  used  for 
evaluation within the individual ages. 










Figure 7. mRNA and protein levels of oligodendrocyte-specific markers were not impaired due to
loss of LRP1. (A) Quantification of the relative expression of Mbp mRNA revealed a time-dependent
upregulation with a significantly higher expression in the KO at P14 (** p ≤ 0.01). (B) Quantification
of the relative expression of Pdgfrα mRNA showed a downregulation from P7 to P56 in the control
and KO. (C) Western blot analysis of protein levels of PDGFRα and MBP. α-tubulin served as the
loading control. (D) Quantification of the relative expression of MBP on protein level demonstrated a
strong time-dependent upregulation of about 100% from P7 t P56. (E) Quantification of the relative
expression of PDGFRα protein level illustrated a tend ntial d wnregulation from P14 to P56. Data are
expressed as the mean ± SEM. PCR: N = 4, n = 4, wes ern blot: N = 3, n = 3. Depending on normally or
not normally distributed data, the Student’s t-test or Mann–Whitney U test was used for evaluation
within the individual ages.
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In summary, the immunohistochemistry, RT-PCR, and western blot results suggested comparable
rates of oligodendrocyte differentiation in response to the tamoxifen treatment excluding strong
unspecific recombination-induced side-effects in our experimental approach, which could interfere
with our analysis of cell-autonomous effects.
3.6. Experimental Autoimmune Encephalomyelitis (EAE)
Oligodendrocytes form myelin sheaths indispensable for integral CNS function and that are
damaged in neuroinflammatory diseases. We wanted to examine whether LRP1 deletion compromises
the myelination by oligodendrocytes. From this perspective, we induced EAE in tamoxifen-treated
animals of both genotypes and sexes at the age of 8 to 10 weeks (P56–P70) and monitored and scored the
animals for four weeks (Figure 8). The two parameters investigated in this study were the body weight
and the clinical score of the animals over four weeks of the disease course (Figure 8B,C). Focusing on
weight first, KO animals started with a slightly higher weight of 19.4 g ± 0.8 g SEM when compared to
the control with 18 g ± 1.8 g SEM.
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According  to  the  clinical  score,  as  an  indicator  for  the  severity  of  symptoms  due  to  EAE 
immunization (Figure 8C), both genotypes responded equally at the beginning of the experiment. A 
score  of  0  revealed  a  lack  of  symptoms  up  to  13  dpi.  Aft rward,  animals  of  both  genotypes 
developed symptoms, reflected by an increased score of 1.6 in the control and 2.2 in the KO (control: 
18 and 20 dpi, KO: 17 and 18 dpi). This score reflected a combination of a reduced tail tonus and 
complete  tail  palsy  in  control  animals  versus  complete  tail  palsy  in  conjunction with  a  lack  of 
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Mann–Whitney U  test was used  for evaluation within  the  individual ages. Score: 0 = normal; 1 = 
reduced  tail  tonus;  2  =  complete  tail palsy;  3  =  lack of  reflexive  compensatory movements while 
walking; 4 = ataxia. 
4. Discussion 
In  order  to  study  LRP1  in  the  oligodendrocyte  lineage,  we  decided  to  generate  a 
tamoxifen‐inducible  conditional mouse  line  as  it  enables  the  selection  of defined  induction  time 
points  for  the  deletion  of  the  gene.  With  our  induction  protocol,  we  benefited  from  the 
NG2‐CreERT2 mouse, which was used to generate our novel model [21]. Depending on the reporter 
genes  eYFP  and  tdTomato,  recombination  efficiencies  of  50–95%  respectively were  observed  by 
Huang et al. [21] and corresponded to our data at P7. 
Figure 8. Experimental allergic encephalomyelitis (EAE) immunization reveals first hints toward more
strongly affected KO animals with greater deficits when compared to the control in the proof of concept
experiment. (A) Timeline of experimental procedure. (B) Diagram of documented weights (g) during
the course of disease over four weeks of control and KO animals. (C) Diagram of relating clinical scores
of the control and KO animals over four weeks of EAE. Data are expressed as the mean ± SEM. N = 5,
n = 5. Depending on normally or not normally distributed data, the Student’s t-test or Mann–Whitney
U test was used for evaluation within the individual ages. Score: 0 = normal; 1 = reduced tail tonus;
2 = complete tail palsy; 3 = lack of reflexive compensatory movements while walking; 4 = ataxia.
Within the first five days post immunization (dpi), a slight decrease of body weight was observed
in both genotypes (control: 17.3 g ± 1.8 g SEM; KO: 18.7 g ± 0.8 g SEM), followed by an increase until
12 or rather 13 dpi, respectively (control: 19.1 g ± 2.1 g SEM; KO: 20.4 g ± 0.8 g SEM) (Figure 8B).
While animals of the control condition remained constant in body weight until the end of the study
(around 18.5–19 g), the KO animals demonstrated a notable reduction in body weight after 12 dpi with
a minimum of 18.2 g ± 1.32 g SEM at 16 and 17 dpi.
The individual KO animals in our study appeared to be clearly affected by the EAE immunization,
as indicated by the diminution in body weight. Following this reduction, the body weight of the
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KO animals increased again (up to 22 dpi), transiting into a stable phase until the end of the study
(Figure 8C).
According to the clinical score, as an indicator for the severity of symptoms due to EAE
immunization (Figure 8C), both genotypes responded equally at the beginning of the experiment.
A score of 0 revealed a lack of symptoms up to 13 dpi. Afterward, animals of both genotypes developed
symptoms, reflected by an increased score of 1.6 in the control and 2.2 in the KO (control: 18 and 20
dpi, KO: 17 and 18 dpi). This score reflected a combination of a reduced tail tonus and complete tail
palsy in control animals versus complete tail palsy in conjunction with a lack of reflexive compensatory
movements while walking in KO animals. The proceeding disease course demonstrated a remitting
phase in both genotypes with decreased scoring until the end of the experiment. In the control, a score
of 0.6 indicated an intermediate stage between normal behavior and reduced tail tonus, whereas the
KO condition was still more strongly affected with a score of 1.2 (Figure 8C). It has to be noted that
our study comprised small collectives revealing mild differences in body weight and clinical score
that did not, however, achieve statistical significance. This may be due to the fact that the majority of
LRP1-deleted OPCs has been eliminated from the CNS of triple transgenic mice, as described above.
Future studies will have to be performed to verify the asserted involvement of LRP1 in the recovery
from EAE.
4. Discussion
In order to study LRP1 in the oligodendrocyte lineage, we decided to generate a
tamoxifen-inducible conditional mouse line as it enables the selection of defined induction time
points for the deletion of the gene. With our induction protocol, we benefited from the NG2-CreERT2
mouse, which was used to generate our novel model [21]. Depending on the reporter genes eYFP and
tdTomato, recombination efficiencies of 50–95% respectively were observed by Huang et al. [21] and
corresponded to our data at P7.
In our study, we present a new triple transgenic mouse model with LRP1-deficiency induced in
postnatal OPCs: NG2-CreERT2ct2/wtxR26eGFPflox/floxxLRP1flox/flox (KO). Deletion of LRP1 in postnatal
OPCs and their progeny resulted in the progressive loss of KO oligodendrocytes during development.
Furthermore, EAE immunization hints at a clear response in LRP1 KO animals. On the cellular level, an
in vitro myelination assay provided initial evidence for modified myelination behavior of recombined
oligodendrocytes, as indicated by elongated internodes in the LRP1 KO condition (Figure S1). Focusing
on the oligodendrocyte lineage, we were able to uncover a new role of LRP1 in oligodendrocyte
survival during development in vivo and potentially also myelin formation in vitro.
In order to target the oligodendrocyte lineage, we induced the KO at P3 and P4 by injection of
tamoxifen to lactating mothers, which metabolized tamoxifen to 4-hydroxy-tamoxifen in the liver [29]
and fed the metabolites to the pups by milk. Early oligodendrocyte development is characterized
by three independent OPC waves, which populate the forebrain at embryonic day (E) 11.5, E15.5,
and P0, and are derived from different sources or structures of the early brain [15,30,31]. Based on
the induction of the KO in young postnatal animals, we wanted to guarantee the deletion of LRP1
from a huge proportion of OPCs in their target compartment and aimed to analyze the effect of the
lineage-restricted LRP1-deficiency in oligodendrocytes over time.
Additional to our focus on the oligodendrocyte lineage, the new mouse model also allowed us to
investigate LRP1-deletion from NG2-glia with an adapted injection protocol (the tamoxifen treatment
can be adjusted depending on the experimental question). The proteoglycan NG2 is not only expressed
in OPCs [18,19], but also in pericytes, which are associated with blood vessels [32]. Pericytes are
known to express LRP1 and therefore could have been affected in our conditional knockout mouse
model. However, our experimental focus was on oligodendrocytes and myelination. Therefore,
we used lineage-specific markers such as PDGFRα, CC1, MBP, and Olig2 to address this aspect in
immunohistochemical stainings. PCR and western blot analysis were used to confirm the effects of
LRP1 deletion on cells of the oligodendrocyte lineage. Additionally, for the in vitro myelination assay
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pure OPC cultures were used to compare LRP1-deficient OPCs with control cells. At present, we cannot
exclude a potential intervention of LRP1-deficient pericytes in the EAE experiment.
OPCs not only exist in the young brain where they differentiate to oligodendrocytes, but
proliferate and can be found throughout the brain into adulthood and were recently termed NG2
glia [33]. These macroglia-like cells in the CNS can generate oligodendrocytes and astrocytes during
development [31,34]. In addition, NG2 glia has been suggested as an immature, progenitor-like cell
type that can differentiate into mature cells with neural properties depending on specific environmental
stimuli [35]. They are present in white and grey matter, but have also been found in stem cell
niches such as the subventricular zone (SVZ) [33,36,37]. So far, nothing is known about LRP1 protein
expression in NG2 glia, but the precursor properties of NG2 glia for oligodendrocyte lineage suggest
an upregulation of LRP1 in NG2 glia. Our triple transgenic mouse model offers new possibilities to
investigate LRP1-deletion in NG2 glia at different deliberately chosen time points. LRP1 deficiency
from neural cell types results in multiple cellular or functional disorders (e.g., apoptosis in neurons [4],
synapse loss and neurodegeneration in aging mice [38], and deficits in chemically induced white matter
lesion repair [16]). Based on the knowledge concerning NG2 glia and LRP1, we propose potential
effects of LRP1 on NG2 glia and their functions.
Deletion of LRP1 in postnatal OPCs in the new mouse model demonstrated a significant
reduction of recombined cells during development. This indicated a progressive loss of
LRP1-deficient oligodendrocytes in the Corpus callosum, the structure with the highest density
of oligodendrocytes [39,40]. From this, we concluded a vulnerable phenotype of LRP1-deficient
oligodendrocytes when compared to the control cells. To examine a potential global reduction of
oligodendrocyte numbers during development due to the progressive loss of KO oligodendrocytes,
we visualized the total fraction of oligodendrocytes with the help of Olig2, a specific lineage
marker [41,42]. Increasing numbers of oligodendrocytes in the Corpus callosum over time support our
interpretation that the progressively lost LRP1-deficient oligodendrocytes are replaced by GFP-negative
non-recombined control cells in the KO over time.
Nevertheless, what happens to the disappearing, presumably weak and vulnerable LRP1 KO
oligodendrocytes? We have previously shown that LRP1-deficient neural stem cells exhibited higher
apoptosis rates when compared to the control conditions [11]. Pro-apoptotic effects in the absence of
LRP1 have also been reported in neurons [4]. From this, we can conclude that the loss of LRP1-deficient
oligodendrocytes could be explained by cell death, presumably apoptosis.
In order to study potential roles in myelination-related diseases, MOG35–55 EAE was induced
in the control and KO animals. EAE is a model that mimics multiple sclerosis pathophysiology
with focal inflammatory, demyelinating lesions, and axonal damage [43,44]. Furthermore, MOG35–55
EAE immunization is expected to generate a monophasic disease course [45], as also confirmed with
our clinical score data. Defects preferentially appear in the spinal cord, but might also occur in the
cerebellum and optic nerve, whereas symptoms are absent from the forebrain (including cortex and
Corpus callosum) [43–45]. In explaining our preliminary findings in affected KO animals, the influences
regarding the immune system should also be considered as the EAE model mimics autoimmune
disease. Previously, anti-inflammatory effects of LRP1 in lipopolysaccharide, tumor necrosis factor
α, and growth factor signaling as well as in phagocytosis have been observed [46]. These reports
suggest an important role of LRP1 in the immune system. On the other hand, the LRP1 deletion
in our model is restricted to the NG2-dependent lineage, and therefore it is questionable whether
the immune system is modified in the EAE study. Furthermore, our observation of vulnerability in
LRP1-deficient KO cells provides the first evidence for impairment in oligodendrocytes and potentially
in myelin in our novel triple transgenic mouse model. Although these data refer to findings in the brain
(Corpus callosum) and not the spinal cord, we expect similar conditions regarding cell fractions and
recombination efficiency in the caudal sections of the CNS. We assumed that the affected KO animals
might point to a late effect of progressive loss of LRP1-deficient oligodendrocytes. It is imaginable
that the regenerative capacity of healthy LRP1-expressing oligodendrocytes is impaired at regions of
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progressive loss of LRP1 KO cells. As a consequence, vulnerable myelin might be formed around those
axons exposed from myelin sheaths of perished oligodendrocytes, which might appear under EAE
disease conditions. This concept will have to be validated by studies designed to eliminate LRP1 from
non-recombined cells in parallel to EAE initiation. Our triple transgenic mouse model offers the option
of timed elimination of LRP1 from OPCs recruited for myelin regeneration.
Based on our assumptions of altered myelin in the KO condition, we performed an in vitro
myelination assay. Here, differentiated OPCs were placed on artificial fibers to investigate potential
myelin impairment (Figure S1). This method allows the lengths of myelin sheaths, or rather internodes,
to be measured [47]. Thereby it enables—and already has been used—to identify alterations in different
conditions (e.g., due to genetically modified OPCs [48]). This myelination assay, performed with
cortex-derived OPCs, revealed seemingly elongated internodes in the KO condition when compared to
the control. Correlated with our findings of EAE, this in vitro study might point to myelin impairment
in NG2-restricted LRP1-deficient mice in vivo. Again, one has to keep in mind that OPCs were
derived from brain structures, and not from spinal cord, although this impaired myelination might
represent a confident target of EAE inflammation. The elongated internodes might also display myelin
dysregulation, referring to impaired thickness and/or wrapping of myelin, which could be addressed
by electron microscopy.
The myelination assay suffered from strongly reduced numbers of surviving recombined KO
cells in the immunopanning procedure and cultivation of cells on fibers. This underlined the weak
and vulnerable KO cell phenotype in vitro and is in agreement with our previous observations.
To circumvent the problems of OPC cultivation, in a future perspective, cells from another mouse
model could be used that shows a higher proportion of recombined (KO) cells.
In addition to our observations regarding LRP1 loss and its marked consequences in the
oligodendrocyte lineage, we also analyzed parameters that revealed a rather mild outcome. Namely,
we concentrated on immature and mature oligodendrocytes in a global (control tissue vs. KO tissue
including recombined and non-recombined cells) and cell-specific manner (control cells in control tissue
vs. recombined cells in KO tissue). Decreasing proportions of precursors and increasing proportions of
mature cells indicated oligodendrocyte differentiation and maturation over time [15,49,50]. mRNA and
protein levels of PDGFRα (precursor marker) and MBP (mature marker) confirmed findings obtained
by immunohistochemistry. Moreover, we found normally behaving and developing KO animals when
compared to the control litter.
Despite the normal appearance of the mice, we found an important role of LRP1 in oligodendrocyte
survival and vulnerability, which suggests a mechanism of compensation in our new model. The first
plausible mechanism relies on the observed replacement of weak and apoptotic cells by healthy control
cells, which might provide an immediate, but not optimum, compensation of cell loss. A second
potential mechanism refers to LRP1 as a member of the low-density lipoprotein (LDL)-receptor gene
family that shares structural elements and multiple functions and might account for compensatory
effects [51]. In addition to LRP1, LRP3, LRP4, and LRP6 are highly expressed in OPCs [9]. LRP2 has
been suggested to mediate OPC proliferation and migration in connection with sonic hedgehog [52].
These properties identify the LRPs as promising candidates for the substitution of specific LRP1
functions after deletion in our new mouse model. To name one function, LDL-receptor family members,
especially LRP1, serve as the main receptors for cholesterol uptake into oligodendrocytes with the
help of apolipoproteins such as ApoE [53]. Cholesterol itself is critically involved in the maturation
of oligodendrocytes and induces myelin-specific gene expression, transports myelin proteins, and
participates in internode formation [54–56].
5. Conclusions
In summary, our novel triple transgenic mouse model provides new insights into the field of
LRP1 and its functions in oligodendrocytes. We found that LRP1-deficiency induced postnatally in
NG2-expressing OPCs led to progressive loss of recombined LRP1 KO oligodendrocytes over time.
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We conclude that LRP1-deficient OPCs are vulnerable and hardly survive. We propose a mechanism of
cell death due to a phenotype susceptible to damage when LRP1 is deleted in the oligodendrocytic
lineage. This was supported by observations in OPC cultures from cortical tissue, where only a few KO
cells could be cultivated that hinted at a modified myelination behavior. In a further step, we found
in an initial study that EAE can be elicited in the triple transgenic mouse line, where individual KO
animals seemed to be clearly affected, yet without statistical significance. This presumably reflects
the fact that most LRP1-deficient OPCs had been eliminated by the time the assay was carried out.
Our model offers the perspective to test the roles of LRP1 by inducing recombination close to the
commencement of inflammatory diseases. This experimental design might help to establish the role of
LRP1 in myelin pathology in future studies.
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Figure S1: Myelinated artificial fibers were examined for the length and the number of myelin sheaths in
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